drugset / Trial / NCT00879086
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study in patients with advanced breast cancer is to compare the incidence and severity of neuropathy adverse events for the two treatment groups (eribulin versus ixabepilone) using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) grading.
Timeline
- Start
- 2009-03-31
- Primary completion
- 2013-04-30
- Completion
- 2014-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Eribulin | Small molecule | 1.4 mg/m2 | Intravenous |
| Comparator | Ixabepilone | Small molecule | 32 mg/m2 | Intravenous |
| Comparator | Ixabepilone | Small molecule | 40 mg/m2 | Intravenous |